Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-08-29

Clinical Trial Update: Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial results report long-term safety and side effects of ruxolitinib in patients with myelofibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ruxolitinib (ruxolitinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myelofibrosis | Phase 2 | Status: COMPLETED | Results posted: 2025-08-29